New administration route for MDS therapy

Article

Azacitidine for injection (Vidaza, Pharmion) can now be given intravenously according to the FDA. Instructions for the new route of administration will be added to the prescribing information, which includes the existing subcutaneous route instructions. Now, azacitidine can be infused over 10 to 40 minutes and the dosing will remain the same for both types of administration—75 mg/m2 daily, for seven days, every four weeks. Azacitidine is approved for treatment of the five subtypes of myelodysplastic syndromes (MDS).

To see more Hot off the Press news articles, click here.

To go to the Drug Topics homepage, click here.

Newsletter

Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.

Recent Videos
2 experts are featured in this series.
2 experts are featured in this series.
2 experts are featured in this series.
2 experts are featured in this series
Image Credit: jokekung - stock.adobe.com
Related Content
© 2025 MJH Life Sciences

All rights reserved.